Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, John F. Seymour, Barbara Eichhorst et al.|Blood Advances|2024Cited by 13
ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic LeukemiaMatthew S. Davids, Othman Al‐Sawaf, Kirsten Fischer et al.|Blood|2021Cited by 12